

CITATION REPORT

List of articles citing

Nicotine receptor partial agonists for smoking cessation

DOI: 10.1002/14651858.cd006103.pub5

Cochrane Database of Systematic Reviews, 2011, , CD006103.

Source: <https://exaly.com/paper-pdf/52037781/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
129	Exercise interventions for smoking cessation. <i>Cochrane Database of Systematic Reviews</i> , 2008, CD002295		80
128	Varenicline for tobacco dependence: panacea or plight?. 2011, 12, 1799-812		13
127	Peripheral artery disease. Part 2: medical and endovascular treatment. 2011, 8, 429-41		31
126	Varenicline and the evaluation of neuropsychiatric adverse events in smokers. 2011, 69, 1017-8		2
125	Chronic obstructive pulmonary disease: a concise review. 2011, 95, 1125-41		34
124	Nicotine dependence and psychological distress: outcomes and clinical implications in smoking cessation. 2011, 4, 119-28		40
123	Varenicline: quantifying the risk. 2011, 183, 1405; author reply 1405, 1407		3
122	Interventions to increase adherence to medications for tobacco dependence. 2011,		1
121	Nicotine receptor partial agonists for alcohol dependence. 2011,		
120	Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study. 2011, 33, 465-77		36
119	Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior. 2011, 82, 984-95		89
118	Mechanistic insights into nicotine withdrawal. 2011, 82, 996-1007		43
117	Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking. 2011, 11, 880		9
116	How do we safely get people to stop smoking?. 2011, 4, 1724-7		0
115	Biomarkers to optimize the treatment of nicotine dependence. 2011, 5, 745-61		14
114	Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. 2011, 183, 1359-66		186
113	Varenicline for smoking cessation: is it a heartbreaker?. 2011, 183, 1346-7		10

112	Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. 2012 , 345, e7176	34
111	A single administration of low-dose varenicline saturates $\alpha 4\beta 2$ * nicotinic acetylcholine receptors in the human brain. <i>Neuropsychopharmacology</i> , 2012 , 37, 1738-48	8.7 24
110	Interventions to increase smoking cessation at the population level: how much progress has been made in the last two decades?. 2012 , 21, 110-8	144
109	Lobeline for smoking cessation. 2012 , CD000124	10
108	Critical limb ischemia: advanced medical therapy. 2012 , 8, 3-9	3
107	Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. 2012 , 344, e2856	136
106	Weight gain in smokers after quitting cigarettes: meta-analysis. 2012 , 345, e4439	295
105	Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers. 2012 , 26, 1383-90	30
104	The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial. 2012 , 91, 172-80	33
103	Interventions for preventing weight gain after smoking cessation. 2012 , 1, CD006219	119
102	Preventive effect of varenicline on impairment of endothelial function in cerebral vessels induced by acute smoking in rats. 2012 , 26, 928-31	8
101	Tobacco cessation in the dental office. 2012 , 56, 747-70	12
100	BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. 2012 , 26, 899-952	204
99	General mechanisms of nicotine-induced fibrogenesis. 2012 , 26, 4778-87	53
98	Strategies to help a smoker who is struggling to quit. 2012 , 308, 1573-80	57
97	Physical activity as an aid to smoking cessation during pregnancy (LEAP) trial: study protocol for a randomized controlled trial. 2012 , 13, 186	26
96	Nicotine receptor partial agonists for smoking cessation. <i>Cochrane Database of Systematic Reviews</i> , 2012 , CD006103	178
95	Interventions to address chronic disease and HIV: strategies to promote smoking cessation among HIV-infected individuals. 2012 , 9, 375-84	32

94	Pharmacological interventions for promoting smoking cessation during pregnancy. <i>Cochrane Database of Systematic Reviews</i> , 2012 , CD010078		86
93	Exercise interventions for smoking cessation. <i>Cochrane Database of Systematic Reviews</i> , 2012 , 1, CD002295		89
92	The effects of varenicline on attention and inhibitory control among treatment-seeking smokers. 2012 , 223, 131-8		28
91	A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch. 2012 , 223, 89-98		13
90	Do placebo response rates from cessation trials inform on strength of addictions?. 2012 , 9, 192-211		13
89	Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. 2012 , 131, 857		32
88	Long-term efficacy and safety of varenicline for smoking cessation: a systematic review and meta-analysis of randomized controlled trials. 2012 , 20, 355-365		6
87	Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. <i>Addiction</i> , 2012 , 107, 1066-73	4.6	225
86	Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation. 2012 , 66, 171-82		18
85	Pharmacologic agents for tobacco dependence treatment: 2011 update. 2012 , 14, 85-92		7
84	Positive allosteric modulation of $\alpha 4 \beta 2$ nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration. 2013 , 230, 203-13		31
83	Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. 2013 , 11, 140		35
82	The role of fatty acid amide hydrolase inhibition in nicotine reward and dependence. 2013 , 92, 458-62		31
81	Translational research in nicotine dependence. 2013 , 3, a012153		9
80	An updated algorithm for choosing among smoking cessation treatments. 2013 , 45, 215-21		19
79	Safety of varenicline among smokers enrolled in the lung HIV study. 2013 , 15, 247-54		32
78	Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. <i>Drug and Alcohol Dependence</i> , 2013 , 133, 486-93	4.9	48
77	Smoking and vascular risk: are all forms of smoking harmful to all types of vascular disease?. 2013 , 127, 435-41		43

76	Dissociable effect of acute varenicline on tonic versus cue-provoked craving in non-treatment-motivated heavy smokers. <i>Drug and Alcohol Dependence</i> , 2013 , 130, 135-41	4.9	22
75	Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System. <i>Addiction</i> , 2013 , 108, 203-10	4.6	35
74	CC4, a dimer of cytisine, is a selective partial agonist at $\alpha 4/\beta 2$ nAChR with improved selectivity for tobacco smoking cessation. 2013 , 168, 835-49		28
73	Behaviour change theory and evidence: a presentation to Government. 2013 , 7, 1-22		154
72	Longitudinal associations between smoking cessation medications and alcohol consumption among smokers in the International Tobacco Control Four Country survey. 2013 , 37, 804-10		11
71	Chronic nicotine exposure stimulates biliary growth and fibrosis in normal rats. 2013 , 45, 754-61		20
70	Pharmacological interventions for smoking cessation: an overview and network meta-analysis. 2013 , CD009329		532
69	Effects of short-term varenicline administration on emotional and cognitive processing in healthy, non-smoking adults: a randomized, double-blind, study. <i>Neuropsychopharmacology</i> , 2013 , 38, 476-84	8.7	28
68	Treatment for tobacco dependence: effect on brain nicotinic acetylcholine receptor density. <i>Neuropsychopharmacology</i> , 2013 , 38, 1548-56	8.7	23
67	The first 7 days of a quit attempt predicts relapse: validation of a measure for screening medications for nicotine dependence. 2013 , 7, 249-54		34
66	Tobacco smoking, quitting, and relapsing among adult males in Mainland China: the China Seven Cities Study. 2013 , 15, 223-30		21
65	Stable Ischemic Heart Disease/Chronic Stable Angina. 2013 , 131-152		
64	Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. 2013 , 70, 522-33		89
63	Environmental and genomic factors as well as interventions influencing smoking cessation: a systematic review of reviews and a proposed working model. 2013 , 16, 159-73		7
62	A preliminary study suggests that nicotine and prefrontal dopamine affect cortico-striatal areas in smokers with performance feedback. 2013 , 12, 554-63		6
61	Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits β -tetrahydrocannabinol-induced central nervous system and heart rate effects in humans. 2013 , 76, 65-77		23
60	Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease. 2013 , 347, 225-34		36
59	Effects of varenicline on abstinence and smoking reward following a programmed lapse. 2013 , 15, 139-48		93

58	Psychosocial interventions for supporting women to stop smoking in pregnancy. <i>Cochrane Database of Systematic Reviews</i> , 2013 , CD001055		173
57	Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. 2013 , 143, e40S-e60S		52
56	Role of nicotine receptor partial agonists in tobacco cessation. 2014 , 56, 17-23		3
55	Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers. 2014 , 17, 223-33		16
54	Relative potency of varenicline or fluvoxamine to reduce responding for ethanol versus food depends on the presence or absence of concurrently earned food. 2014 , 38, 860-70		9
53	Tobacco use and cessation for cancer survivors: an overview for clinicians. 2014 , 64, 272-90		79
52	Culturally-Tailored Smoking Cessation for Adult American Indian Smokers: A Clinical Trial. 2014 , 42, 852-886		19
51	The Saudi Guidelines for the Diagnosis and Management of COPD. 2014 , 9, 55-76		31
50	Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia. 2014 , 231, 765-75		23
49	The cytisine derivatives, CC4 and CC26, reduce nicotine-induced conditioned place preference in zebrafish by acting on heteromeric neuronal nicotinic acetylcholine receptors. 2014 , 231, 4681-93		24
48	Pharmacological strategies for detoxification. 2014 , 77, 302-14		32
47	Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. 2014 , 231, 3843-53		40
46	Dual role of nicotine in addiction and cognition: a review of neuroimaging studies in humans. <i>Neuropharmacology</i> , 2014 , 84, 111-22	5.5	111
45	Cannabinoids and the brain: New hopes for new therapies. 2014 , 175-218		
44	Motivational interviewing for smoking cessation. 2015 , CD006936		118
43	Evaluation of the cardiovascular effects of varenicline in rats. 2015 , 9, 5705-17		15
42	Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse. <i>Neuropsychopharmacology</i> , 2015 , 40, 2185-97	8.7	70
41	Potential Conflict of Interest and Bias in the RACGP'S Smoking Cessation Guidelines: Are GPs Provided with the Best Advice on Smoking Cessation for their Patients?. 2015 , 8, 319-331		7

40	The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises?. 2015 , 2, 105-10		106
39	Cardiovascular adverse events associated with smoking-cessation pharmacotherapies. 2015 , 17, 554		1
38	A comparison of the effectiveness of varenicline and transdermal nicotine patch in outpatients following a standardized smoking cessation program in Southern Taiwan. 2015 , 38, 115-25		7
37	Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers. 2015 , 29, 833-45		9
36	Smoking cessation strategies for patients with asthma: improving patient outcomes. 2016 , 9, 117-28		18
35	Critical Role of Cannabinoid CB1 Receptors in Nicotine Reward and Addiction. 2016 , 158-167		
34	Nicotine receptor partial agonists for alcohol dependence. 2016 ,		
33	A comparison of neuropsychiatric adverse events during early treatment with varenicline or a nicotine patch. <i>Addiction</i> , 2016 , 111, 1283-92	4.6	15
32	Nicotine receptor partial agonists for smoking cessation. 2016 , CD006103		156
31	Safety of Varenicline for Smoking Cessation in Psychiatric and Addicts Patients. 2016 , 51, 649-57		7
30	Reduction of nicotine self-administration by chronic nicotine infusion with H1 histamine blockade in female rats. 2016 , 233, 3009-15		6
29	Exercise to Enhance Smoking Cessation: the Getting Physical on Cigarette Randomized Control Trial. <i>Annals of Behavioral Medicine</i> , 2016 , 50, 358-69	4.5	21
28	Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016 , 65, 269-87	5.5	26
27	Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys. <i>Neuropsychopharmacology</i> , 2016 , 41, 2283-93	8.7	42
26	Pharmacotherapy in smoking cessation: Corticotropin Releasing Factor receptors as emerging intervention targets. <i>Neuropeptides</i> , 2017 , 63, 49-57	3.3	2
25	An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use. <i>Addiction</i> , 2018 , 113, 1673	4.6	8
24	Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. <i>Addiction</i> , 2018 , 113, 1696	4.6	56
23	Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a G β protein inhibitor. <i>Neuropharmacology</i> , 2018 , 133, 107-120	5.5	12

22	Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation. <i>Addiction Biology</i> , 2018 , 23, 291-303	4.6	24
21	The effectiveness of Cytisine versus Nicotine Replacement Treatment for smoking cessation in the Russian Federation. <i>International Journal of Drug Policy</i> , 2018 , 58, 121-125	5.5	6
20	Smoking, alcohol, and nutritional status in relation to one-year mortality in Danish stage I lung cancer patients. <i>Lung Cancer</i> , 2018 , 124, 40-44	5.9	6
19	Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials. <i>Therapeutic Advances in Respiratory Disease</i> , 2019 , 13, 1753466619875925	4.9	6
18	Nicotine Reward and Abstinence: Role of the CB1 Receptors. 2019 , 297-304		
17	Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized clinical replication trial with frequent users. <i>Drug and Alcohol Dependence</i> , 2020 , 206, 107700	4.9	21
16	Nicotine Dependence: Current Treatments and Future Directions. 2020 , 399-410.e5		1
15	Possible therapeutic applications of cannabis in the neuropsychopharmacology field. <i>European Neuropsychopharmacology</i> , 2020 , 36, 217-234	1.2	16
14	Tobacco Cessation Approaches and Impact on CVD. <i>Global Heart</i> , 2012 , 7, 129-38	2.9	1
13	Suchterkrankungen. 2012 , 291-346		2
12	Acute activation, desensitization and smoldering activation of human acetylcholine receptors. <i>PLoS ONE</i> , 2013 , 8, e79653	3.7	38
11	Net improvement of correct answers to therapy questions after pubmed searches: pre/post comparison. <i>Journal of Medical Internet Research</i> , 2013 , 15, e243	7.6	3
10	The London Exercise And Pregnant smokers (LEAP) trial: a randomised controlled trial of physical activity for smoking cessation in pregnancy with an economic evaluation. <i>Health Technology Assessment</i> , 2015 , 19, vii-xxiv, 1-135	4.4	19
9	Mechanisms for nicotine in the development and progression of gastrointestinal cancers. 2012 , 1, 81-87		27
8	A Discussion about Modalities of Smoking Cessation in Perioperative Phase for Addicts: A Review Article. <i>Journal of Addiction Medicine and Therapeutic Science</i> , 004-008	0.3	
7	Eficacia y seguridad del uso de medicamentos para la cesaci3n de la adicci3n al tabaco: revisi3n de gu3as de pr3ctica cl3nica. <i>Revista De Salud Publica</i> , 2015 , 16, 772-785	0.2	1
6	Effects of varenicline on lung tissue in the animal model. <i>Jornal Brasileiro De Pneumologia</i> , 2020 , 46, e20180406		
5	PURLs: Counseling is a must with this smoking cessation aid. <i>Journal of Family Practice</i> , 2012 , 61, 156-76	0.2	

- 4 Smoking cessation therapy during pregnancy. *Canadian Family Physician*, **2012**, 58, 525-7 0.9 11
- 3 Smoking cessation by combined medication and counselling: a feasibility study in lung cancer patients. *BMC Pulmonary Medicine*, **2022**, 22, 3-5
- 2 The MD Anderson Cancer Center Moon Shots Program[®] : A Global Priority. **2023**, 619-628
- 1 Effectiveness of Varenicline and Cytisine for Alcohol Use Reduction Among People With HIV and Substance Use. **2022**, 5, e2225129